Viemed Healthcare, Inc. reported substantial growth for fiscal year 2025, with net revenue increasing 21% year-over-year to $270.3 million. The company generated $14.9 million in net income and delivered a record $61.4 million in adjusted EBITDA. This performance reflects continued platform momentum and contributions from the Lehan's acquisition, supported by industry tailwinds from the shift toward in-home care and accelerating adoption of sleep and resupply services.
The company's growth trajectory faces both opportunities and challenges. A key development is the transition within Viemed's business model, where sleep and resupply services are now overtaking ventilation in importance. This shift improves the quality of recurring revenue and reduces the company's sensitivity to regulatory changes. The acquisition of Lehan's has broadened Viemed's commercial exposure, diversified its payer mix, and created a longer runway for scaled growth. More information on the company's performance is available in the full research update from Stonegate Capital Partners.
Despite these positive trends, Viemed encountered a temporary headwind from the updated National Coverage Determination (NCD) for ventilators. The new policy added documentation requirements and tightened coverage criteria, which moderated ventilator patient growth in the short term. Importantly, reimbursement levels were not changed by the update, and ventilator activity has already begun to normalize. The company ended the fiscal year with free cash flow up 141% year-over-year, indicating strong financial health.
For business and technology leaders, Viemed's results highlight several critical industry implications. The healthcare sector's accelerated transition to in-home care models creates significant opportunities for companies with established platforms and diversified service offerings. Viemed's strategic pivot toward sleep/resupply services demonstrates how healthcare providers can reduce regulatory risk while building more predictable revenue streams. The company's ability to maintain growth despite temporary regulatory friction suggests operational resilience that may be undervalued by the market.
Looking ahead, Viemed's guidance for FY26 and current valuation suggest that durable growth prospects may remain underappreciated. While margin mix pressure exists as the business evolves, the company's diversified approach positions it to capitalize on multiple healthcare trends simultaneously. For investors and industry observers, Viemed's performance offers a case study in navigating regulatory changes while leveraging structural shifts in healthcare delivery toward more convenient, cost-effective home-based solutions.
